assessment of a Melissa extract capsule effects on lowering TG blood levels in diabetics

Assessment of a herbal extract capsule of Melissa officinalis on lowering triglyceride blood levels in type 2 diabetic patients : a randomized double blind placebo controlled study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2015112625251N1

Enrollment

Registered

2016-03-07

Start date

2016-02-19

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes mellitus. Diabetes mellitus

Interventions

Intervention 1: intervention group: taking orally, 2 herbal capsules of 350 mg mellissa officinalis extract per day ( one after breakfast and one after dinner) for 3 months . capsules are provided by

Treatment - Drugs

intervention group: taking orally, 2 herbal capsules of 350 mg mellissa officinalis extract per day ( one after breakfast and one after dinner) for 3 months . capsules are provided by professor kamali

placebo group: taking orally 2 similar capsules of corn starch per day for 3 months

Eligibility

Sex/Gender

All

Age

20 Years to 65 Years

Inclusion criteria

Inclusion criteria: inclusion criteria: diabetic patients aged 20y to 65y.; Hb A1C less than 8.5 %; TG more than 150 mg in dl up to 500 mg in dl exclusion criteria:any systemic disease; severe diabetic complication; neoplasia; psycologic diseases;pregnancy and lactation; smoking and addiction; any drug consumption with effects on lipid metabolism within the last month except of anti diabetic agents

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Serum TG. Timepoint: 0- 1m-2m-3m. Method of measurement: biochemical analysis.;HDL-LDL-Chol. Timepoint: 0- 1m-2m-3m. Method of measurement: biochemical analysis.;FBS. Timepoint: 0- 1m-2m-3m. Method of measurement: biochemical analysis.	—

Secondary

Measure	Time frame
HbA1c. Timepoint: before-3m. Method of measurement: biochemical analysis.;AST-ALT-ALKP. Timepoint: before-3m. Method of measurement: biochemical analysis.;BUN-CRE. Timepoint: before-3m. Method of measurement: biochemical analysis.;Systolic & diastolic blood pressure. Timepoint: before-3m. Method of measurement: Sphygmomanometer.;BMI. Timepoint: before-3m. Method of measurement: formula.;Anthropometric measures. Timepoint: before-3m. Method of measurement: standardized meter.;Side effects. Timepoint: before-3m. Method of measurement: check list.	—

Measure

Time frame

HbA1c. Timepoint: before-3m. Method of measurement: biochemical analysis.;AST-ALT-ALKP. Timepoint: before-3m. Method of measurement: biochemical analysis.;BUN-CRE. Timepoint: before-3m. Method of measurement: biochemical analysis.;Systolic & diastolic blood pressure. Timepoint: before-3m. Method of measurement: Sphygmomanometer.;BMI. Timepoint: before-3m. Method of measurement: formula.;Anthropometric measures. Timepoint: before-3m. Method of measurement: standardized meter.;Side effects. Timepoint: before-3m. Method of measurement: check list.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Kamalinegad

Shahid Beheshti university of medical sciences- department of pharmacognosis and pharmaceutical Biot

mkamalinegad@yahoo.com+98 21 8820 0115

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026